ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR2
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR2
8
trial(s) found.
NCT06082167
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
STELLAR-305
)
MET/VEGFR2/AXL/MER inhibitor
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ anti-VEGFR2 monoclonal antibody
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
SA
5037 - Glandore - Ashford Cancer Centre
NCT04986852
Advanced
Phase 2
Recruiting
A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (
KEYNOTE-C14
)
anti-PD-1 monoclonal antibody
anti-VEGFR2 monoclonal antibody
Triple-negative breast cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ VEGFR2 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12619001655134
Haem
Phase 2
Recruiting
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (
INTERVENE
) Acute Myeloid Leukaemia
Bcl2 inhibitor
+ VEGFR2 inhibitor
Acute myeloid leukaemia
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Enrolling by invitation (1)
Unknown (1)
Recruitment Country and State
NSW (5)
SA (4)
VIC (4)
WA (2)
QLD (2)
NZ (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (6)
Paed (1)
Haem (1)
Cancer Therapy Class
VEGFR2
100%
PD-1/PD-L1
75%
PD-1
63%
KIT
63%
AXL
50%
MET
50%
VEGFR
50%
PDGFR
38%
RET
38%
MER
25%
ROS1
25%
CDK4
13%
CDK6
13%
HIF2a
13%
ERBB2
13%
HPK1
13%
LAG3
13%
OX40
13%
PARP
13%
TIGIT
13%
VEGF
13%
VEGFR1
13%
VEGFR3
13%
Bcl2
13%
FLT3
13%
HDAC
13%
PKC
13%
AR
13%
CYP17A1
13%
PD-L1
13%
androgen axis
13%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4032 - Chermside - The Prince Charles Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
Cancer Type
Cancer
Solid tumour
Kidney cancer
Urogenital cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Non-clear cell renal cell carcinoma
Clear cell renal cell carcinoma
Breast adenocarcinoma
Breast cancer
Triple-negative breast cancer
Acute myeloid leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
Differentiated thyroid carcinoma
Endocrine gland cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy